These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 15315996)

  • 21. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate.
    Hara I; Miyake H; Yamada Y; Takechi Y; Hara S; Gotoh A; Fujisawa M; Okada H; Arakawa S; Soejima T; Sugimura K; Kamidono S
    Int J Urol; 2002 Jun; 9(6):322-8; discussion 328. PubMed ID: 12269247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
    Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
    Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
    Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
    Akyol F; Ozyigit G; Selek U; Karabulut E
    Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
    Alexander A; Crook J; Jones S; Malone S; Bowen J; Truong P; Pai H; Ludgate C
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):23-30. PubMed ID: 19395187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Mameghan H; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; D'Este C;
    Lancet Oncol; 2005 Nov; 6(11):841-50. PubMed ID: 16257791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
    Mirhadi AJ; Zhang Q; Hanks GE; Lepor H; Grignon DJ; Peters CA; Rosenthal SA; Zeitzer K; Radwan JS; Lawton C; Parliament MB; Reznik RS; Sandler HM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):511-515. PubMed ID: 28126300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.
    Michalski J; Winter K; Roach M; Markoe A; Sandler HM; Ryu J; Parliament M; Purdy JA; Valicenti RK; Cox JD
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e363-70. PubMed ID: 22633552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
    Roach M; Lu J; Pilepich MV; Asbell SO; Mohiuddin M; Grignon D
    J Urol; 2003 Jan; 169(1):245-50. PubMed ID: 12478146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
    Royce TJ; Chen MH; Wu J; Loffredo M; Renshaw AA; Kantoff PW; D'Amico AV
    JAMA Oncol; 2017 May; 3(5):652-658. PubMed ID: 28097317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.
    Wo JY; Chen MH; Nguyen PL; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
    J Clin Oncol; 2009 Dec; 27(35):6000-5. PubMed ID: 19858385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison.
    Perez CA; Michalski JM; Purdy JA; Wasserman TH; Williams K; Lockett MA
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):629-37. PubMed ID: 10837945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
    Corn BW; Winter K; Pilepich MV
    Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma].
    Geinitz H; Zimmermann F; von Wedel E; Thamm R; Busch R; Feldmann HJ; Molls M
    Strahlenther Onkol; 2002 Jul; 178(7):369-77. PubMed ID: 12163991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.